SRR2770872
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.400
- PANCREAS_BETA_CELLS+0.300
- PROTEIN_SECRETION+0.300
- ADIPOGENESIS+0.200
- BILE_ACID_METABOLISM+0.200
- SPERMATOGENESIS+0.200
- ANDROGEN_RESPONSE+0.100
- HEME_METABOLISM+0.100
- MYC_TARGETS_V1+0.100
- MYOGENESIS+0.100
Top 10 suppressed
- ANGIOGENESIS-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- INTERFERON_ALPHA_RESPONSE-0.400
- INTERFERON_GAMMA_RESPONSE-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- WNT_BETA_CATENIN_SIGNALING-0.400
- E2F_TARGETS-0.300
- G2M_CHECKPOINT-0.300
- HYPOXIA-0.300
- IL6_JAK_STAT3_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR660969 | GTEX | — | 0.854 |
| 2 | SRR10900001 | — | — | 0.850 |
| 3 | SRR8518272 | — | E | 0.847 |
| 4 | SRR655134 | GTEX | — | 0.847 |
| 5 | SRR657754 | GTEX | — | 0.845 |
| 6 | SRR1420984 | GTEX | — | 0.845 |
| 7 | SRR659235 | GTEX | — | 0.840 |
| 8 | SRR661325 | GTEX | — | 0.831 |
| 9 | SRR12202427 | — | — | 0.830 |
| 10 | SRR661445 | GTEX | — | 0.829 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| MYC_TARGETS_V1 | 0.100 | Inavolisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |